SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?
Publication
, Journal Article
Al Rifai, M; Newby, LK; Nair, AP; Misra, A; Rogers, JG; Fedson, S; Virani, SS
Published in: Curr Atheroscler Rep
August 2022
PURPOSE OF REVIEW: In this review, we discuss the mechanisms of action of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and the purported protective effects for mitigating heart failure (HF)-related outcomes. RECENT FINDINGS: Major randomized clinical trials have demonstrated the cardiovascular safety and efficacy of SGLT-2i among patients without known HF and those with established HF with reduced ejection fraction or preserved ejection fraction (HFrEF and HFpEF respectively). Recent HF guidelines have incorporated SGLT-2i in HF treatment algorithms. SGLT-2i have emerged as a novel treatment for both prevention of HF and reduction of cardiovascular morbidity and mortality among patients with existing HFrEF or HFpEF.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Curr Atheroscler Rep
DOI
EISSN
1534-6242
Publication Date
August 2022
Volume
24
Issue
8
Start / End Page
627 / 634
Location
United States
Related Subject Headings
- Ventricular Function, Left
- Stroke Volume
- Sodium-Glucose Transporter 2 Inhibitors
- Humans
- Heart Failure
- Cardiovascular System & Hematology
- 3201 Cardiovascular medicine and haematology
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Al Rifai, M., Newby, L. K., Nair, A. P., Misra, A., Rogers, J. G., Fedson, S., & Virani, S. S. (2022). SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently? Curr Atheroscler Rep, 24(8), 627–634. https://doi.org/10.1007/s11883-022-01038-2
Al Rifai, Mahmoud, L Kristin Newby, Ajith P. Nair, Arunima Misra, Joseph G. Rogers, Savitri Fedson, and Salim S. Virani. “SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?” Curr Atheroscler Rep 24, no. 8 (August 2022): 627–34. https://doi.org/10.1007/s11883-022-01038-2.
Al Rifai M, Newby LK, Nair AP, Misra A, Rogers JG, Fedson S, et al. SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently? Curr Atheroscler Rep. 2022 Aug;24(8):627–34.
Al Rifai, Mahmoud, et al. “SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?” Curr Atheroscler Rep, vol. 24, no. 8, Aug. 2022, pp. 627–34. Pubmed, doi:10.1007/s11883-022-01038-2.
Al Rifai M, Newby LK, Nair AP, Misra A, Rogers JG, Fedson S, Virani SS. SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently? Curr Atheroscler Rep. 2022 Aug;24(8):627–634.
Published In
Curr Atheroscler Rep
DOI
EISSN
1534-6242
Publication Date
August 2022
Volume
24
Issue
8
Start / End Page
627 / 634
Location
United States
Related Subject Headings
- Ventricular Function, Left
- Stroke Volume
- Sodium-Glucose Transporter 2 Inhibitors
- Humans
- Heart Failure
- Cardiovascular System & Hematology
- 3201 Cardiovascular medicine and haematology
- 1102 Cardiorespiratory Medicine and Haematology